Key Points:

• TRex Bio plans to raise $125 million by offering 8.3 million shares at $14 to $16 each, implying a fully diluted market value of $453 million at the midpoint.
• The Phase 1 biotech is developing therapies designed to restore immune balance by augmenting regulatory T cells in inflamed human tissue rather than broadly suppressing the immune system.
• Eli Lilly plans to invest $13 million in the IPO and is also a discovery partner, while TRex Bio’s lead candidate is expected to deliver Phase 1b data in mid-2027.

TRex Bio, a clinical-stage biotechnology company developing treatments for autoimmune and inflammatory diseases, has set terms for a proposed $125 million US IPO. The South San Francisco-based company plans to offer 8.3 million shares at $14 to $16 each, with the midpoint valuing the company at approximately $453 million on a fully diluted basis. The offering comes as TRex Bio advances a pipeline built around regulatory T cells, or Tregs, as a potential way to restore immune balance in inflamed tissues.

Company Background: Targeting Immune Regulation

TRex Bio is developing medicines designed to augment regulatory T cells in inflamed human tissue. Rather than broadly suppressing immune activity, the company’s approach seeks to restore immune balance and repair damaged tissue barriers. Its discovery strategy is supported by a proprietary Deep Biology platform that maps Treg function in fresh human skin, gut and lung tissue to identify potential therapeutic targets.

The company then validates those targets through a proprietary in vitro Treg model and a high-throughput functional assay suite. This platform has produced multiple development candidates, including programs being advanced independently by TRex Bio and through its relationship with Eli Lilly.

IPO Details: $125 Million Offering

TRex Bio plans to raise $125 million through the sale of 8.3 million shares at $14 to $16 each. At the midpoint, the proposed offering implies a fully diluted market capitalization of approximately $453 million. Eli Lilly intends to purchase approximately $13 million of shares, representing about 10% of the offering.

The supplied source does not disclose a final ticker symbol, exchange listing or underwriting syndicate. The IPO would provide additional capital as TRex Bio advances its clinical programs, with the company’s development timeline making upcoming trial data an important consideration for prospective public-market investors.

Pipeline and Market Opportunity

TRex Bio’s lead candidate, TRB-061, is a TNFR2 agonist currently in a Phase 1b trial for moderate-to-severe atopic dermatitis. Topline data are expected in mid-2027. A second wholly owned candidate, TRB-071, targets CD30 for inflammatory bowel disease and is expected to enter Phase 1 in the first half of 2027.

Eli Lilly’s involvement adds strategic significance to the platform. In addition to participating in the IPO, Lilly is a discovery partner and is advancing a third candidate identified through TRex Bio’s platform into a Phase 2a trial for lupus. The relationship potentially provides validation for the company’s target-discovery approach while expanding the commercial development opportunities around its technology.

Risks and Challenges

As a Phase 1 biotechnology company, TRex Bio faces substantial clinical and regulatory risks. The therapeutic hypothesis behind its Treg-focused approach must translate into measurable clinical benefits, while candidates entering early-stage trials remain subject to safety and efficacy uncertainty. The company also operates in competitive autoimmune and inflammatory disease markets where established therapies and emerging mechanisms are vying for market share.

For investors assessing TRex Bio’s market debut, the key question is whether its Deep Biology platform can consistently generate clinically meaningful therapies and whether the company’s lead programs can validate the approach. The $453 million midpoint valuation places significant importance on future clinical execution, making the 2027 data milestones and Lilly relationship central factors in determining investor interest following the IPO.